Danaher to Acquire Masimo in $9.9 Billion Deal to Enhance Diagnostics Portfolio

Danaher Corporation has announced its intention to acquire Masimo Corporation, a manufacturer of pulse oximeters, for $9.9 billion. The deal, which involves a purchase price of $180 per share, represents a 38.3% premium over Masimo's last closing price. This acquisition marks Danaher's largest transaction since its $5.7 billion purchase of Abcam in 2023 and is part of the company's strategy to strengthen its diagnostics portfolio amid challenges in the life sciences sector.

CNBC

The acquisition of Masimo is expected to allow Danaher to diversify its offerings by integrating non-invasive patient monitoring technologies, such as pulse oximeters, into its existing product lineup, which includes invasive blood analysis devices from its Radiometer brand. This move comes at a time when life science firms face uncertainties related to drug pricing regulations, potential tariff policies, and reduced funding for academic and government research.

CNBC

Danaher anticipates that the acquisition will positively impact its financial performance, projecting an increase in adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year post-acquisition, and approximately $0.70 by the fifth year. As of now, Masimo has a market capitalization of around $7 billion, while Danaher is valued at over $150 billion.

CNBC

Following the announcement, Masimo's stock surged by 34.3% to $174.89 in premarket trading, reflecting investor optimism about the acquisition. Conversely, Danaher's shares fell by 6.1%, indicating a mixed market response to the news.

CNBC

Masimo has been involved in a protracted legal battle with Apple Inc. over patent infringements related to blood-oxygen reading technology. A federal jury in California recently ordered Apple to pay Masimo $634 million for these infringements, which may have implications for Masimo's financial health and its attractiveness as an acquisition target.

CNBC

While the acquisition is generally viewed as a strategic move for Danaher, some analysts express concerns regarding the integration of Masimo's technologies and the potential challenges posed by ongoing legal issues. Critics argue that the complexities of merging different corporate cultures and operational systems could hinder the anticipated benefits of the acquisition.

CNBC

Danaher and Masimo expect the acquisition to close by the second half of 2026, pending regulatory approvals and other customary closing conditions. The successful integration of Masimo's technologies into Danaher's existing operations will be closely monitored by industry analysts and investors alike.

CNBC